Header Logo

Connection

CHARLES WYKOFF to Refraction, Ocular

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Refraction, Ocular.
CHARLES WYKOFF
Connection Strength
0.096
Refraction, Ocular
  1. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
    View in: PubMed
    Score: 0.096
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.